Skip to content

Ceredex Value Advisors LLC: VTR position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Ceredex Value Advisors LLC on VTR, newest first. How the timeline and the estimate are built.

Ceredex Value Advisors LLC held 270,350 VTR shares at 2026-06-30 per its 13F-HR filed 2026-08-11.

the latest 13F is the newest step

  1. period ended2026-06-30
    13F 270,350 shares
    Change vs previous 13F +9,900 shares

    0.68% of the 13F portfolio, value $24,007,080.

    13F-HR 0001738726-26-000006 filed by Ceredex Value Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2026-03-31
    13F 260,450 shares
    Change vs previous 13F 0 shares

    0.67% of the 13F portfolio, value $21,299,601.

    13F-HR 0001738726-26-000004 filed by Ceredex Value Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2025-12-31
    13F 260,450 shares
    Change vs previous 13F -98,050 shares

    0.61% of the 13F portfolio, value $20,153,621.

    13F-HR 0001738726-26-000002 filed by Ceredex Value Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2025-09-30
    13F/A 358,500 shares
    Change vs previous 13F -98,450 shares

    0.58% of the 13F portfolio, value $25,091,415.

    13F-HR/A 0001628280-25-052325 filed by Ceredex Value Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2025-06-30
    13F 456,950 shares
    Change vs previous 13F not available

    0.62% of the 13F portfolio, value $28,856,393.

    13F-HR 0001587281-25-000003 filed by Ceredex Value Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).